# Diaceutics PLC 57.9% potential upside indicated by Canaccord Genuity

- Link: https://www.directorstalkinterviews.com/diaceutics-plc-57.9-potential-upside-indicated-by-canaccord-genuity/4121129085
- Published: 2023-10-10T12:16:20+01:00
- Author: Charlotte Edwards

**Diaceutics PLC** with ticker (LON:DXRX) now has a potential upside of 57.9% according
to Canaccord Genuity.
Canaccord Genuity set a target price of 150 GBX for the company,
which when compared to the Diaceutics PLC share price of 95 GBX at opening today(
10/10/2023) indicates a potential upside of 57.9%. Trading has ranged between 74(
52 week low) and 118 (52 week high) with an average of 77,426 shares exchanging 
hands daily. The market capitalisation at the time of writing is £80,299,480.Diaceutics
PLC is a United Kingdom-based technology and solutions provider to the pharmaceutical
industry. The principal activities of the Company and its subsidiaries are data,
data analytics and implementation services. The Company offers a core suite of products
and outsourced advisory services, which helps its pharma customers to optimize and
deliver their marketing and implementation strategies for companion diagnostics.
Its DRDX Data Solutions include Physician Mapping, Lab Mapping, DXRX Signal AND 
DXRX Disease Testing Rate Tracker. Its Tech Enabled Services include DXRX Lab Report
Optimization, DXRX Lab Quality Assessment, DXRX Education, DXRX Advisory Board, 
DXRX Lab Alerts and DXRX for Labs. Its DXRX-The Diagnostic Network is a diagnostic
commercialization platform for precision medicine, integrating multiple pipelines
of real-world diagnostic testing data from a global network of laboratories.

Share on: